Qiming Stars | Three Qiming Venture Partners Portfolio Companies Named to KPMG China Biotech Innovation 50 List
These awards do more than give industry leaders a stage to showcase their achievements — they offer a deep reflection on the innovative resilience and growth potential of China's biotech sector.
Recently, KPMG China unveiled its third annual Biotech Innovation 50 list. The selection not only offers a platform for industry leaders to showcase their achievements, but also serves as a deep commentary on the innovative resilience and growth potential of China's biotech sector.
Portfolio companies of Qiming Venture Partners — Shize Biotech, Touche Future, and Ze'an Biopharmaceutical — made the list.
Shize Biotech, Touche Future, and Ze'an Biopharmaceutical selected for KPMG China Biotech Innovation 50 list
· KPMG China Biotech Innovation 50
This year's list evaluates companies across six dimensions: technological and product leadership, pipeline breadth and proportion of original R&D, background of core management and R&D teams, commercialization prospects, capital market activity, and financial health. The selected enterprises span biopharmaceuticals, cell and gene therapy, in vitro diagnostics, medical devices, CRO/CDMO, AI-driven drug discovery, and other sub-sectors.
Chinese biopharma companies are currently accelerating their international expansion, growing their R&D pipelines, and increasing cross-border transactions. License-out deals and Newco structures are helping companies enhance their global competitiveness. At the same time, the industry's innovation ecosystem continues to improve, financing channels are diversifying, and deeper collaboration between academia, industry, and investors is injecting sustained vitality into the sector.
Going forward, Chinese biotech companies are expected to integrate into global innovation networks with greater openness, leveraging accumulated technical strengths, extensive R&D experience, and vast market opportunities to distinguish themselves in global competition.
Source | KPMG China
Past Highlights
Qiming Honors | Qiming Venture Partners and 50+ Portfolio Companies Named to 2025 Future Healthcare 100 List Qiming Stars | 20+ Qiming Portfolio Companies Selected for 2025 China Future Unicorn Top 100 and Other Lists Qiming Honors | Qiming Venture Partners and Portfolio Companies Win Multiple Awards at 2024 Medical Device Industry Innovation Ecosystem Assessment
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management of $9.5 billion. Since its inception, the firm has focused on investing in outstanding early- and growth-stage companies in Technology and Consumer (T&C) and Healthcare.
To date, Qiming has invested in over 580 high-growth innovative companies. More than 210 of these have gone public on the NYSE, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many Qiming portfolio companies have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ:WRD), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), SinoCellTech (688520.SH), Yuanxin Technology, ClinChoice, Belief BioMed, Biren Technology, and others.